<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1526">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04714515</url>
  </required_header>
  <id_info>
    <org_study_id>01032020-7</org_study_id>
    <nct_id>NCT04714515</nct_id>
  </id_info>
  <brief_title>Montelukast - a Treatment Choice for COVID-19</brief_title>
  <official_title>Using Montelukast to Treat the Patients Infected With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sargodha</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shaukat Khanum Memorial Cancer Hospital &amp; Research Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Teesside University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sargodha</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study aimed to make a therapeutic comparison and effectiveness of&#xD;
      Hydroxychloroquine (HCQ) and Montelukast (ML) in COVID-19 patients in addition to the&#xD;
      standard of care. The safety and efficacy of HCQ and ML will be assessed as individual&#xD;
      therapy and in combination with each other and with the standard of care. Cytokine storm&#xD;
      (Interleukin levels) also will be monitored throughout the study to assess treatment&#xD;
      progression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To date, no specific medication is available for COVID-19. Many FDA-approved drugs, including&#xD;
      antivirals, antibacterials, and anti-inflammatory compositions are being tested with the&#xD;
      intention of repurposing against COVID-19. In this study, investigators have evaluated the&#xD;
      effectiveness of Hydroxychloroquine (HCQ) and Montelukast (ML) in an individual and&#xD;
      combination therapy.&#xD;
&#xD;
      Investigators have performed an observational study of 100 hospitalized COVID-19 patients&#xD;
      while assessing the safety and efficacy of HCQ, ML, and IV as individual therapy and in&#xD;
      combination with each other. ECG, interleukin levels, LFTs, blood profiles were continuously&#xD;
      monitored throughout the study.&#xD;
&#xD;
      The aim was to observe participants treated with ML and monitor the inflammatory markers to&#xD;
      see whether they increase or decrease and whether an increase in survival rate is observed.&#xD;
      The findings have shown that combinational therapy of ML with continuous observation of&#xD;
      liver/kidney profiles and QTc prolongation can provide robust recovery with suppression of&#xD;
      cytokines.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 20, 2020</start_date>
  <completion_date type="Actual">April 20, 2020</completion_date>
  <primary_completion_date type="Actual">March 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patients admittance to ICU</measure>
    <time_frame>2 Week</time_frame>
    <description>Changes in the number of ICU visits of COVID-19 patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Length of total stay at the hospital</measure>
    <time_frame>2 weeks</time_frame>
    <description>Changes in the length of total stay of patients at the hospital</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alleviating the symptoms of COVID-19</measure>
    <time_frame>2 weeks</time_frame>
    <description>Monitoring the changes in disease severity with alleviation of the symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interleukin levels</measure>
    <time_frame>1 Week</time_frame>
    <description>Monitoring the Interleukin levels with the progression of treatments</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">150</enrollment>
  <condition>Covid19</condition>
  <condition>SARS-CoV-2 Infection</condition>
  <arm_group>
    <arm_group_label>Hydroxychloroquine and Montelukast</arm_group_label>
    <description>Group 1 was given Standard of care (SOC) + HCQ + Montelukast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Montelukast</arm_group_label>
    <description>Group 2 was given Standard of care (SOC) + Montelukast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <description>Group 3 was given Standard of care (SOC) + HCQ</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydroxychloroquine, Montelukast and Invermectin</arm_group_label>
    <description>Group 4 was given Standard of care (SOC) + Montelukast + HCQ and Ivermectin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast</intervention_name>
    <description>An FDA approved medicine to treat asthmatic patients</description>
    <arm_group_label>Hydroxychloroquine and Montelukast</arm_group_label>
    <arm_group_label>Hydroxychloroquine, Montelukast and Invermectin</arm_group_label>
    <arm_group_label>Montelukast</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>An FDA approved antiarthritis drug</description>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <arm_group_label>Hydroxychloroquine and Montelukast</arm_group_label>
    <arm_group_label>Hydroxychloroquine, Montelukast and Invermectin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin</intervention_name>
    <description>An FDA approved anti-parasitic medicine</description>
    <arm_group_label>Hydroxychloroquine, Montelukast and Invermectin</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Nasal Swab samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients, who were admitted to the hospitals with SARS-CoV-2 contacts (environmental&#xD;
        exposure or close contact) or obvious COVID-19 symptoms and were diagnosed with COVID-19&#xD;
        using the PCR tests. Consent was obtained from all patients with a detailed history of any&#xD;
        known co-morbidities.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with diagnosed COVID-19&#xD;
&#xD;
          -  Patients who are not directly admitted to ICU&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients, who were already on immunosuppressants&#xD;
&#xD;
          -  Patients with age &gt; 80&#xD;
&#xD;
          -  Patient with any known allergies to montelukast&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Critical Care Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Muhammad Rehman Akram, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shaukat Khanum Memorial Cancer Hospital &amp; Research Centre, Johar Town, Lahore, Pakistan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Critical Care Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaukat Khanum Memorial Cancer Hospital &amp; Research Centre, Johar Town, Lahore, Pakistan</name>
      <address>
        <city>Lahore</city>
        <state>Punjab</state>
        <zip>54600</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 19, 2020</study_first_submitted>
  <study_first_submitted_qc>January 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2021</study_first_posted>
  <last_update_submitted>January 15, 2021</last_update_submitted>
  <last_update_submitted_qc>January 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sargodha</investigator_affiliation>
    <investigator_full_name>Muhammad Fayyaz ur Rehman</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Montelukast</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Ivermectin</mesh_term>
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

